Chengdu Zenitar Biomedical Technology Co., Ltd
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS12
PHASE 3 / 2-32
RECRUITING7
READOUTS ≤12 MONTHS2
READOUT SLIPPED >6 MO38%
Delay Index: of 8 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Chengdu Zenitar Biomedical Technology Co., Ltd on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Flonoltinib 50mg NCT06457425 |
P2 | Active, not recruiting | MF,PMF,PPV-MF,PET-MF | 75 | 2025-11-26 (-5 mo) |
| Purinostat Mesylate 4 mg/m2 NCT06484829 |
P1/2 | Recruiting | Relapsed or Refractory Multiple Myeloma (RRMM) | 144 | 2026-02-01 |
| A0/B0 group Purinostat Mesylate 11.2mg/m2 NCT06431243 |
P1/2 | Recruiting | Advanced Solid Tumor | 132 | 2026-05-01 |
| 11.2 mg/m2 Purinostat Mesylate NCT06485219 |
P2 | Active, not recruiting | Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL); Cutaneous T-cell Lymphoma (CTCL) | 50 | 2026-06-30 (+7 mo) |
| PM 8.4 mg/m^2 NCT05563844 |
P2 | Active, not recruiting | Diffuse Large B Cell Lymphoma,DLBCL | 74 | 2026-12-30 (+24 mo) |
| Flonoltinib 75mg NCT07232290 |
P2 | Recruiting | Polycythemia Vera (PV) | 60 | 2027-07-30 |
| The high-dose group of ZL-82 tablets NCT07193589 |
P2 | Recruiting | Atopic Dermatitis | 111 | 2027-12-30 (+12 mo) |
| Flonoltinib Maleate NCT07443306 |
P2 | Recruiting | MF | 64 | 2027-12-30 |
| Flonoltinib 75mg NCT07317700 |
P3 | Recruiting | MF | 105 | 2027-12-30 |
| ZL-85FA tablets NCT07339748 |
P1/2 | Not yet recruiting | Advanced Solid Tumor | 51 | 2028-06-30 |
| FM-MF-02 NCT07750574 |
P2 | Not yet recruiting | Myelofibrosis; Myelofibrosis Due to and Following Polycythemia Vera | 105 | 2028-11 |
| Purinostat Mesylate for Injection NCT07011056 |
P3 | Recruiting | Recurrent and Refractory Diffuse Large B-cell Lymphoma | 390 | 2029-06-30 |